Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.95 USD | +2.35% | +15.83% | +48.06% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.06% | 1.99B | |
+49.21% | 56.87B | |
+37.35% | 39.72B | |
-6.86% | 39.27B | |
-4.42% | 28.73B | |
+12.00% | 26.21B | |
-18.27% | 19.79B | |
+29.57% | 12.28B | |
+25.41% | 12.23B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor